In addition, efficacy with AAV9 has also been demonstrated in multiple Batten diseases, including CLN3, CLN6, and CLN8, using other routes of administration (48–50). This evidence concerns the gene CLN3 and juvenile neuronal ceroid lipofuscinosis.